SUMMIT CLINICAL RESEARCH SOLUTIONS EXPANDS PINNACLE SITE NETWORK WITH ACQUISITION OF DALLAS RESEARCH INSTITUTE

Summit Clinical Research Solutions has announced the acquisition of Dallas Research Institute (DRI) for an undisclosed amount, a transaction that took place on September 10, 2026. This acquisition is aimed at expanding Summit's Pinnacle site network and enhancing its expertise in the fields of metabolic and liver diseases. The integration of DRI into Summit's operations is expected to bolster its presence in the Dallas-Fort Worth metroplex, a key market for clinical research.

Dallas Research Institute, established in 2024, specializes in complex clinical trials related to metabolic diseases, including Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH). The institute has built a reputation for strong patient recruitment capabilities and community engagement, which are critical for the successful execution of clinical trials. DRI's focus aligns closely with Summit's therapeutic expertise, particularly in metabolic conditions and obesity, making this acquisition a strategic fit.

The Dallas-Fort Worth area represents one of the largest and fastest-growing metropolitan statistical areas in the United States, providing a fertile ground for clinical research. With this acquisition, Summit not only expands its operational footprint but also enhances its ability to attract and retain sponsors looking for robust clinical trial sites. Summit currently operates two additional sites in the DFW area, and the addition of DRI is expected to further strengthen its competitive position in this vital market.

Dr. Pedro Castillo Jr., who has been serving as the Principal Investigator at DRI since its inception, will continue in this role post-acquisition. His ongoing leadership is anticipated to facilitate a smooth transition and maintain the high standards of clinical research that DRI is known for. The acquisition is seen as a natural extension of Summit's commitment to high-quality clinical research and patient care, aligning with the vision of the late Dr. Stephen Harrison, a co-founder of both Summit and Pinnacle.

The broader implications of this acquisition point to a continuing trend of consolidation within the healthcare sector, particularly in clinical research. As companies seek to enhance their capabilities and expand their geographic reach, strategic acquisitions like that of DRI by Summit are likely to become more common. This transaction underscores the increasing importance of specialized research sites in the competitive landscape of clinical trials, particularly in high-growth therapeutic areas such as metabolic diseases.